| Real-world experience with ceftazidime-avibactam for multidrug-resistant gram-negative bacterial infections SCJ Jorgensen, TD Trinh, EJ Zasowski, AM Lagnf, S Bhatia, SM Melvin, ... Open forum infectious diseases 6 (12), ofz522, 2019 | 109 | 2019 |
| Bacteriophage therapeutics: a primer for clinicians on phage‐antibiotic combinations T Morrisette, R Kebriaei, KL Lev, S Morales, MJ Rybak Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40 (2 …, 2020 | 80 | 2020 |
| On-and off-label utilization of dalbavancin and oritavancin for Gram-positive infections T Morrisette, MA Miller, BT Montague, GR Barber, RB McQueen, M Krsak Journal of Antimicrobial Chemotherapy 74 (8), 2405-2416, 2019 | 71 | 2019 |
| Long-acting lipoglycopeptides:“lineless antibiotics” for serious infections in persons who use drugs T Morrisette, MA Miller, BT Montague, GR Barber, RB McQueen, M Krsak Open forum infectious diseases 6 (7), ofz274, 2019 | 60 | 2019 |
| Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections T Morrisette, S Alosaimy, JV Philley, C Wadle, C Howard, AJ Webb, ... Open Forum Infectious Diseases 8 (2), ofab002, 2021 | 42 | 2021 |
| Cefiderocol: a novel Siderophore cephalosporin against multidrug‐resistant gram‐negative pathogens JC Abdul‐Mutakabbir, S Alosaimy, T Morrisette, R Kebriaei, MJ Rybak Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40 (12 …, 2020 | 41 | 2020 |
| Bacteriophage-antibiotic combination strategy: an alternative against methicillin-resistant phenotypes of Staphylococcus aureus R Kebriaei, K Lev, T Morrisette, KC Stamper, JC Abdul-Mutakabbir, ... Antimicrobial agents and chemotherapy 64 (7), 10.1128/aac. 00461-20, 2020 | 40 | 2020 |
| Real-world, multicenter experience with meropenem-vaborbactam for gram-negative bacterial infections including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa S Alosaimy, AM Lagnf, T Morrisette, MR Scipione, JJ Zhao, ... Open forum infectious diseases 8 (8), ofab371, 2021 | 39 | 2021 |
| Advantages of outpatient treatment with long‐acting lipoglycopeptides for serious gram‐positive infections: a review M Krsak, T Morrisette, M Miller, K Molina, M Huang, L Damioli, L Pisney, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40 (5 …, 2020 | 36 | 2020 |
| The pharmacokinetic and pharmacodynamic properties of hydroxychloroquine and dose selection for COVID-19: putting the cart before the horse T Morrisette, TP Lodise, MH Scheetz, S Goswami, JM Pogue, MJ Rybak Infectious diseases and therapy 9, 561-572, 2020 | 33 | 2020 |
| Early experience with eravacycline for complicated infections S Alosaimy, KC Molina, KC Claeys, J Andrade, J Truong, MA King, ... Open Forum Infectious Diseases 7 (5), ofaa071, 2020 | 33 | 2020 |
| Bacteriophage-antibiotic combinations for Enterococcus faecium with varying bacteriophage and daptomycin susceptibilities T Morrisette, KL Lev, R Kebriaei, JC Abdul-Mutakabbir, KC Stamper, ... Antimicrobial agents and chemotherapy 64 (9), 10.1128/aac. 00993-20, 2020 | 31 | 2020 |
| Oral vancomycin prophylaxis as secondary prevention against Clostridioides difficile infection in the hematopoietic stem cell transplantation and hematologic malignancy population T Morrisette, AG Van Matre, MA Miller, SW Mueller, V Bajrovic, MZ Abidi, ... Biology of Blood and Marrow Transplantation 25 (10), 2091-2097, 2019 | 31 | 2019 |
| The emerging role of β-lactams in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections KC Molina, T Morrisette, MA Miller, V Huang, DN Fish Antimicrobial Agents and Chemotherapy 64 (7), 10.1128/aac. 00468-20, 2020 | 29 | 2020 |
| The evolving reduction of vancomycin and daptomycin susceptibility in MRSA—salvaging the gold standards with combination therapy T Morrisette, S Alosaimy, JC Abdul-Mutakabbir, R Kebriaei, MJ Rybak Antibiotics 9 (11), 762, 2020 | 24 | 2020 |
| Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections In Vitro: Bacteriophage-Antibiotic Combination R Kebriaei, KL Lev, RM Shah, KC Stamper, DJ Holger, T Morrisette, ... Microbiology Spectrum 10 (2), e00411-22, 2022 | 23 | 2022 |
| Early multicenter experience with imipenem-cilastatin-relebactam for multidrug-resistant gram-negative infections N Rebold, T Morrisette, AM Lagnf, S Alosaimy, D Holger, K Barber, ... Open Forum Infectious Diseases 8 (12), ofab554, 2021 | 22 | 2021 |
| Monotherapy with vancomycin or daptomycin versus combination therapy with β-lactams in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: a … S Alosaimy, NL Sabagha, AM Lagnf, EJ Zasowski, T Morrisette, ... Infectious Diseases and Therapy 9, 325-339, 2020 | 21 | 2020 |
| Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections D Holger, R Kebriaei, T Morrisette, K Lev, J Alexander, M Rybak Antibiotics 10 (5), 556, 2021 | 18 | 2021 |
| Phage Cocktails with Daptomycin and Ampicillin Eradicates Biofilm-Embedded Multidrug-Resistant Enterococcus faecium with Preserved Phage Susceptibility AJK Coyne, K Stamper, R Kebriaei, DJ Holger, A El Ghali, T Morrisette, ... Antibiotics 11 (9), 1175, 2022 | 15 | 2022 |
